Safety and Tolerability of Neoadjuvant Radiotherapy Combined With Anti-PD-1 Antibody Toripalimab for Locally Advanced, Resectable Esophageal Squamous Cell Cancer: A Prospective Phase IB Trial

被引：0
|
作者：
Sun, H. [1 ]
Yang, W. [1 ]
Luo, J. [1 ]
Lin, H. [1 ]
Zhou, T. [2 ]
Gong, H. [3 ]
Zhao, D. [1 ]
Niu, Z. [1 ]
Liu, B. [1 ]
Wang, Z. [4 ]
Li, B. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[4] Shandong Canc Hosp, Jinan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1014
引用
收藏
页码：S102 / S103
页数：2
相关论文
共 50 条
  • [31] Neoadjuvant trial with toripalimab, albumin paclitaxel, and cisplatin on pathological response in locally advanced resectable oral squamous cell carcinoma (Illuminate Trial).
    Zhong, Lai-Ping
    Huang, Ying-Ying
    Sun, Jing-Jing
    Li, Jun
    Dong, Min-Jun
    Zhu, Guopei
    Li, Jiang
    Ju, Wu-Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18067 - E18067
  • [32] Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial
    Meng, Xiangrui
    Qi, Yu
    Shan, Zhengzheng
    Yang, Yang
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Preoperative chemoradiation and cetuximab for resectable, locally advanced esophageal cancer: Preliminary results of a prospective phase Ib/II trial.
    Brenner, Baruch
    Kundel, Yulia
    Purim, Ofer
    Medalia, Gal
    Olshinka, Liran
    Kashtan, Hanoch
    Menasherov, Nikolai
    Fenig, Eyal
    Sulkes, Aaron
    Idelevich, Efraim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
    Yang, Bo
    Guo, Xiaofeng
    Le, Cheng
    Su, Wenzhong
    Li, Xiaoming
    Zhang, Yanfeng
    Yang, Guangyi
    Liang, Weimin
    Zheng, Zhixin
    Wu, Junpeng
    Zhang, Yaowen
    Hao, Anlin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [35] The efficacy and safety of toripalimab combined with definitive chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Xi, Mian
    Zhu, Yujia
    Li, Qiao-Qiao
    Zhao, Lei
    Yang, Yadi
    Hu, Yonghong
    Liu, Mengzhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
    Shen, Dijian
    Chen, Qixun
    Wu, Jie
    Li, Jianqiang
    Tao, Kaiyi
    Jiang, Youhua
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (01) : 1 - 10
  • [37] Phase II trial of terelizumab combined with radiotherapy of locally advanced unresectable esophageal squamous cell carcinoma: TREC trial
    Liu, Changmin
    Yu, Zeshun
    Hao, Yanzhang
    Wang, Feng
    Wang, Zhenbo
    Tian, Lijun
    Wang, Yue
    Ning, Fangling
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer
    Wang, F.
    He, M-M.
    Yao, Y-C.
    Wang, Z-Q.
    Jin, Y.
    Wang, F-H.
    Qiu, M-Z.
    Lv, Z-D.
    Wang, S.
    Luo, H-Y.
    Li, Y-H.
    Zhang, D-S.
    Xu, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S425 - S425
  • [39] Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.
    Liu, Chengixn
    Huang, Wei
    Fu, Chengrui
    Sun, Hongfu
    Zhao, Qian
    Zhao, Changhong
    Chen, Xiaoyu
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [40] Phase 2 Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-surgical Therapy for Locally Advanced Oral Cavity Cancer
    Kaczmar, J.
    Kompelli, A.
    Graboyes, E.
    Hornig, J.
    Lentsch, E.
    Day, T.
    Paulos, C.
    Young, M. R.
    Neskey, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1315 - 1315
12345